|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Interest-earning deposits in other banks | ||||||||||||||||||||
| Federal funds sold | ||||||||||||||||||||
| Total cash and cash equivalents | ||||||||||||||||||||
| Securities | ||||||||||||||||||||
| Available-for-sale, at fair value | ||||||||||||||||||||
| Held-to-maturity; fair value of $151,607 in 2026 and $161,052 in 2025 ($0 credit loss allowance for 2026 and 2025) | ||||||||||||||||||||
| Equity securities | ||||||||||||||||||||
| Restricted stock, at cost | ||||||||||||||||||||
| Total securities | ||||||||||||||||||||
| Loans held for sale | ||||||||||||||||||||
| Loans | ||||||||||||||||||||
| Less allowance for credit losses | ||||||||||||||||||||
| Net loans | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Bank-owned life insurance | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Accrued interest receivable and other assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||||||||||||
| LIABILITIES | ||||||||||||||||||||
| Deposits | ||||||||||||||||||||
| Noninterest-bearing | ||||||||||||||||||||
| Interest-bearing | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Short-term borrowings | ||||||||||||||||||||
| Other borrowings | ||||||||||||||||||||
| Allowance for credit losses on off-balance sheet commitments | ||||||||||||||||||||
| Accrued interest payable and other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||||||||||||
| Common stock, $6.25 par value. Authorized 9,000,000 shares; issued 2,980,602 shares; outstanding 2,627,015 shares in 2026 and 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Treasury stock at cost: 353,587 shares in 2026 and 2025 | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total shareholders' equity | ||||||||||||||||||||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||||||||||||
Loading...
